Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron and Nicotine Patch for Tobacco Withdrawal
NCT00000289Phase 2
Key facts
- Status
- Completed
- Start
- May 1998
- Countries
- 1
- Sponsor
- National Institute on Drug Abuse
- Modality
- Small Molecules
- Drugs
- ondansetron
- Conditions
- Tobacco Use Disorder (TUD)
01
Overview
Phase 2 trial of ondansetron in Tobacco Use Disorder (TUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Subjective effects, Physiological effects and 1 more. Started May 1998; status: completed.
02
Design
2 armsOndansetron + Nicotine Patch
Subjects receive various doses of ondansetron in combination with the nicotine patch.
Nicotine Patch Alone
Subjects receive the nicotine patch alone as an active control.
03
Who it enrols
Male/Female subjects ages 21-45 years inclusive, with a smoking history of at least 15 cigarettes daily for at least 1 yr, in good health, motivated to stop smoking, and having experienced at least 4 withdrawal symptoms upon abstinence.
04
Endpoints
Primary
Subjective effects
Physiological effects
Performance effects
Beyond the preview
Go deeper on NCT00000289.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000289.